Carmen Annevelink

Ms. Carmen Annevelink

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 July 2023 in Journal of Clinical Lipidology
Verified
Journal Article
Open access
CACarmen Annevelink
Carmen Annevelink
PSPhilip Sapp
Philip Sapp
KPKristina S. Petersen
Kristina S. Petersen
GSGreg C. Shearer
Greg C. Shearer
PKPenny Kris-Etherton
Penny Kris-Etherton
Palmitic acid is the predominant dietary saturated fatty acid (SFA) in the US diet. Plasma palmitic acid is derived from dietary fat and also endogenously from de novo lipogenesis (DNL) and lipolysis. DNL is affected by excess energy intake resulting in overweight and obesity, and the macronutrient profile of the diet. A low-fat diet (higher carbohydrate and/or protein) promotes palmitic acid synthesis in adipocytes and the liver. A high-fat diet is another source of palmitic acid that is taken up by adipose tissue, liver, heart and skeletal muscle via lipolytic mechanisms. Moreover, overweight/obesity and accompanying insulin resistance increase non-esterified fatty acid (NEFA) production. Palmitic acid may affect cardiovascular disease (CVD) risk via mechanisms beyond increasing LDL-C, notably synthesis of ceramides and possibly through branched fatty acid esters of hydroxy fatty acids (FAHFAs) from palmitic acid. Ceramides are positively associated with incident CVD, whereas the role of FAHFAs is uncertain. Given the new evidence about dietary regulation of palmitic acid metabolism there is interest in learning more about how diet modulates circulating palmitic acid concentrations and, hence, potentially CVD risk. This is important because of the heightened interest in low carbohydrate (carbohydrate controlled) and high carbohydrate (low-fat) diets coupled with the ongoing overweight/obesity epidemic, all of which can increase plasma palmitic acid levels by different mechanisms. Consequently, learning more about palmitic acid biochemistry, trafficking and how its metabolites affect CVD risk will inform future dietary guidance to further lower the burden of CVD.

22 October 2022 in Metabolites
Verified
Journal Article
Open access
PDF file
CACarmen Annevelink
Carmen Annevelink
Rachel E WalkerRachel E Walker
Rachel E Walker
GSGregory Shearer
Gregory Shearer
Oxylipins are oxygenated metabolites of fatty acids that share several similar biochemical characteristics and functions to fatty acids including transport and trafficking. Oxylipins are most commonly measured in the non-esterified form which can be found in plasma, free or bound to albumin. The non-esterified form, however, reflects only one of the possible pools of oxylipins and is by far the least abundant circulating form of oxylipins. Further, this fraction cannot reliably be extrapolated to the other, more abundant, esterified pool. In cells too, esterified oxylipins are the most abundant form, but are seldom measured and their potential roles in signaling are not well established. In this review, we examine the current literature on experimental oxylipin measurements to describe the lack in reporting the esterified oxylipin pool. We outline the metabolic and experimental importance of esterified oxylipins using well established roles of fatty acid trafficking in non-esterified fatty acids and in esterified form as components of circulating lipoproteins. Finally, we use mathematical modeling to simulate how exchange between cellular esterified and unesterified pools would affect intracellular signaling.. The explicit inclusion of esterified oxylipins along with the non-esterified pool has the potential to convey a more complete assessment of the metabolic consequences of oxylipin trafficking.

20 March 2025 in Nutrients
Verified
Journal Article
Open access
PDF file
CACarmen Annevelink
Carmen Annevelink
JWJason Westra
Jason Westra
NTNathan Tintle
Nathan Tintle
GSGregory Shearer
Gregory Shearer
Objectives: The objective of this study is to outline a framework for how fatty acids may be acting as mediators/suppressors and/or moderators of an individual’s genetic predisposition for cardiovascular lipid biomarkers. Methods: All UK Biobank participants with demographic and lifestyle variables, circulating cardiovascular lipids, and NMR-measured fatty acid data collected at the baseline visit (N = 229,859) were included in analyses. We fit four separate linear regression models, one for each of the following common measures of cardiovascular lipids: total cholesterol, HDL-c, LDL-c, and total triglycerides. Each model predicted cardiovascular lipids by an individual’s FADS (a well-known fatty acid desaturase gene complex) haplotype, with the addition of individual ω-3 (DHA, non-DHA, and total), ω-6 (LA, non-LA, and total), or SFA factors as additive (mediation/suppression) or using an interaction term (with FADS) (moderation). All models were adjusted for a wide range of demographic and medical history variables and evaluated against a Bonferroni-adjusted significance level (p < 8.9 × 10−4). Results: Across 56 models (four lipids × seven FAs × two conceptual models (mediation/suppression and moderation)), we found evidence of 19 moderation, 12 mediation, and 16 suppression effects of the FADS–lipid relationship. For example, adjusting for circulating DHA levels as a mediator, the association of the genotype with HDL-c substantially lessened for both minor genotypes reflecting >122% mediation of the association of FADS by DHA. Additionally, we found evidence that LDL-c is moderated, to some extent, by all fatty acid measures. Conclusions: This analysis demonstrates that an individual’s fatty acid profile can act as a mediator/suppressor or moderator of the association of the FADS genotype and various cardiovascular biomarkers. Future work is necessary to expand this cross-sectional examination to determine directionality and temporality of the mediation and moderation evidence presented. This research has been conducted using the UK Biobank Resource under Application Number 85092.

20 February 2026 in International Journal of Obesity
Verified
Journal Article
Open access
PDF file
CACarmen Annevelink
Carmen Annevelink
DTDebra K. M. Tacad
Debra K. M. Tacad
HAHooman Allayee
Hooman Allayee
KSKristen Sutton
Kristen Sutton
CDCatherine Dombroski
Catherine Dombroski
BBBrian J. Bennett
Brian J. Bennett
Background: Understanding how genetic factors interact with diet and lifestyle to influence obesity is critical as we move towards models of precision nutrition and medicine. Objectives: To assess how genetic and lifestyle factors influence the variation in body composition and metabolic syndrome (Metsyn) risk factors. Methods: A cross-sectional sample of age/sex/BMI-balanced 18–66 year old men and women ( n = 211) from the USDA Nutritional Phenotyping Study were included in the analysis (NCT02367287). BMI polygenic risk scores (PRS) were calculated with the pgs_calc pipeline. Associations with body composition and Metsyn traits were assessed by linear regression and ANCOVA. Explained variance was evaluated using sum of squares and partial R², with model constraint using Bayesian information criteria. Results: The PRS independently explained 15.6% of BMI variance and, after adjusting for age, sex, and genetic population structure, accounted for 11.3% of BMI variance ( p ANCOVA = 1.1 × 10⁻⁷). Measures of diet quality, fitness, and resting metabolic rate (RMR) showed mixed independent associations with obesity traits. In best fit models, while the PRS was significant for DXA outcomes, waist circumference, and fasting TG, the explained variance was below 3% except in android-to-gynoid ratio (3.3%), lean mass index (6.6%), and waist circumference (10.1%). The BMI PRS showed subtle associations with the metabolic/physiological consequences of obesity, only waist circumference and plasma glucose were associated with PRS. Blood pressure, triglycerides, and HDL levels were not associated with PRS for obesity. Conclusions: The genetic factors influencing BMI appear to differ from those contributing to measures of adiposity and metabolic consequences of obesity. Genetic risk of high BMI was validated in this cohort, but sex, RMR, and fitness are the more refined determinants of adiposity and dysregulated metabolism in this healthy population. Future research should be sure to utilize genetic risk predictors specifically associated with maladaptive obesity traits rather than more broad associated phenotypes. Clinical trial registry: NCT02367287